Cat. No.: HY-100789

ON1231320

Name: ON1231320
Brand: MedChemExpress
SKU: HY-100789
Price: 52.00 USD
Availability: InStock
Rating: 5 (3 reviews)

3 Cited Publications

Customer Review

Based on 3 publication(s) in Google Scholar

ON1231320 is a highly specific polo like kinase 2 (PLK2) inhibitor with an IC₅₀ of 0.31 μM. ON1231320 blocks tumor cell cycle progression in the G2/M phase in mitosis, causing apoptotic cell death. ON1231320, an arylsulfonyl pyrido-pyrimidinone, has antitumor activity.

For research use only. We do not sell to patients.

Purity : 99.90%
CAS No.: 1312471-39-8
Formula: C₂₂H₁₅F₂N₅O₃S
Molecular Weight:467.45

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

ON1231320 Chemical Structure

CAS No.: 1312471-39-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (3)
Solvent & Solubility
- In Vitro
- In Vivo
Protocols (8)
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

^[1]

PLK2

0.31 μM (IC₅₀)

PLK1

>10 μM (IC₅₀)

PLK3

>10 μM (IC₅₀)

PLK4

>10 μM (IC₅₀)

All Polo-like Kinase (PLK) Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
5637	GI₅₀	0.125 μM Compound: 7ao; ON1231320	Growth inhibition of human 5637 cells after 72 hrs by trypan blue assay Growth inhibition of human 5637 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
A-431	GI₅₀	0.03 μM Compound: 7ao; ON1231320	Growth inhibition of human A431 cells after 72 hrs by trypan blue assay Growth inhibition of human A431 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
A549	GI₅₀	0.075 μM Compound: 7ao; ON1231320	Growth inhibition of human A549 cells after 72 hrs by trypan blue assay Growth inhibition of human A549 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
ASPC1	GI₅₀	0.3 μM Compound: 7ao; ON1231320	Growth inhibition of human AsPC1 cells after 72 hrs by trypan blue assay Growth inhibition of human AsPC1 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
Bel-7402	GI₅₀	0.05 μM Compound: 7ao; ON1231320	Growth inhibition of human Bel7402 cells after 72 hrs by trypan blue assay Growth inhibition of human Bel7402 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
BT-474	GI₅₀	0.1 μM Compound: 7ao; ON1231320	Growth inhibition of human BT474 cells after 72 hrs by trypan blue assay Growth inhibition of human BT474 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
BT-549	GI₅₀	0.25 μM Compound: 7ao; ON1231320	Growth inhibition of human BT549 cells after 72 hrs by trypan blue assay Growth inhibition of human BT549 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
BXPC-3	GI₅₀	0.075 μM Compound: 7ao; ON1231320	Growth inhibition of human BxPC3 cells after 72 hrs by trypan blue assay Growth inhibition of human BxPC3 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
CAPAN-1	GI₅₀	0.075 μM Compound: 7ao; ON1231320	Growth inhibition of human Capan1 cells after 72 hrs by trypan blue assay Growth inhibition of human Capan1 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
CCRF-CEM	GI₅₀	0.05 μM Compound: 7ao; ON1231320	Growth inhibition of human CEM cells after 72 hrs by trypan blue assay Growth inhibition of human CEM cells after 72 hrs by trypan blue assay	[PMID: 26762835]
COLO 205	GI₅₀	0.075 μM Compound: 7ao; ON1231320	Growth inhibition of human COLO205 cells after 72 hrs by trypan blue assay Growth inhibition of human COLO205 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
Daudi	GI₅₀	0.075 μM Compound: 7ao; ON1231320	Growth inhibition of human Daudi cells after 72 hrs by trypan blue assay Growth inhibition of human Daudi cells after 72 hrs by trypan blue assay	[PMID: 26762835]
DU-145	IC₅₀	0.075 μM Compound: 7ao; ON1231320	Growth inhibition of human DU145 cells after 72 hrs by trypan blue assay Growth inhibition of human DU145 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
Granta-519	GI₅₀	0.04 μM Compound: 7ao; ON1231320	Growth inhibition of human GRANTA-519 cells after 72 hrs by trypan blue assay Growth inhibition of human GRANTA-519 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
HCC1806	GI₅₀	0.1 μM Compound: 7ao; ON1231320	Growth inhibition of human HCC1806 cells after 72 hrs by trypan blue assay Growth inhibition of human HCC1806 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
HCT-116	GI₅₀	0.15 μM Compound: 7ao; ON1231320	Growth inhibition of human HCT116 cells after 72 hrs by trypan blue assay Growth inhibition of human HCT116 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
HeLa	GI₅₀	0.05 μM Compound: 7ao; ON1231320	Growth inhibition of human HeLa cells after 72 hrs by trypan blue assay Growth inhibition of human HeLa cells after 72 hrs by trypan blue assay	[PMID: 26762835]
HepG2	GI₅₀	0.5 μM Compound: 7ao; ON1231320	Growth inhibition of human HepG2 cells after 72 hrs by trypan blue assay Growth inhibition of human HepG2 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
HFL1	GI₅₀	>2 μM Compound: 7ao; ON1231320	Growth inhibition of human HFL1 cells after 72 hrs by trypan blue assay Growth inhibition of human HFL1 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
HL-60	GI₅₀	0.125 μM Compound: 7ao; ON1231320	Growth inhibition of human HL60 cells after 72 hrs by trypan blue assay Growth inhibition of human HL60 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
Jurkat	GI₅₀	0.025 μM Compound: 7ao; ON1231320	Growth inhibition of human Jurkat cells after 72 hrs by trypan blue assay Growth inhibition of human Jurkat cells after 72 hrs by trypan blue assay	[PMID: 26762835]
K562	IC₅₀	0.075 μM Compound: 7ao; ON1231320	Growth inhibition of human K562 cells after 72 hrs by trypan blue assay Growth inhibition of human K562 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
LNCaP	GI₅₀	0.04 μM Compound: 7ao; ON1231320	Growth inhibition of human LNCAP cells after 72 hrs by trypan blue assay Growth inhibition of human LNCAP cells after 72 hrs by trypan blue assay	[PMID: 26762835]
MCF7	GI₅₀	0.075 μM Compound: 7ao; ON1231320	Growth inhibition of human MCF7 cells after 72 hrs by trypan blue assay Growth inhibition of human MCF7 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
MDA-MB-436	GI₅₀	0.15 μM Compound: 7ao; ON1231320	Growth inhibition of human MDA-MB-436 cells after 72 hrs by trypan blue assay Growth inhibition of human MDA-MB-436 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
MDA-MB-453	GI₅₀	0.075 μM Compound: 7ao; ON1231320	Growth inhibition of human MDA-MB-453 cells after 72 hrs by trypan blue assay Growth inhibition of human MDA-MB-453 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
MIA PaCa-2	GI₅₀	0.075 μM Compound: 7ao; ON1231320	Growth inhibition of human MIAPaCa2 cells after 72 hrs by trypan blue assay Growth inhibition of human MIAPaCa2 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
NCI-H1650	GI₅₀	0.2 μM Compound: 7ao; ON1231320	Growth inhibition of human NCI-H1650 cells after 72 hrs by trypan blue assay Growth inhibition of human NCI-H1650 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
NCI-H1734	GI₅₀	0.15 μM Compound: 7ao; ON1231320	Growth inhibition of human NCI-H1734 cells after 72 hrs by trypan blue assay Growth inhibition of human NCI-H1734 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
NCI-H1975	GI₅₀	0.075 μM Compound: 7ao; ON1231320	Growth inhibition of human NCI-H1975 cells after 72 hrs by trypan blue assay Growth inhibition of human NCI-H1975 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
NCI-H23	GI₅₀	0.2 μM Compound: 7ao; ON1231320	Growth inhibition of human H23 cells after 72 hrs by trypan blue assay Growth inhibition of human H23 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
NCI-H292	GI₅₀	0.15 μM Compound: 7ao; ON1231320	Growth inhibition of human NCI-H292 cells after 72 hrs by trypan blue assay Growth inhibition of human NCI-H292 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
NCI-H460	GI₅₀	0.1 μM Compound: 7ao; ON1231320	Growth inhibition of human H460 cells after 72 hrs by trypan blue assay Growth inhibition of human H460 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
Panc1005	GI₅₀	0.4 μM Compound: 7ao; ON1231320	Growth inhibition of human Panc 10.05 cells after 72 hrs by trypan blue assay Growth inhibition of human Panc 10.05 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
PC-3	GI₅₀	0.15 μM Compound: 7ao; ON1231320	Growth inhibition of human PC3 cells after 72 hrs by trypan blue assay Growth inhibition of human PC3 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
PLC-PRF-5	GI₅₀	0.75 μM Compound: 7ao; ON1231320	Growth inhibition of human PLC/PRF/5 cells after 72 hrs by trypan blue assay Growth inhibition of human PLC/PRF/5 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
Raji	GI₅₀	0.05 μM Compound: 7ao; ON1231320	Growth inhibition of human Raji cells after 72 hrs by trypan blue assay Growth inhibition of human Raji cells after 72 hrs by trypan blue assay	[PMID: 26762835]
RT-4	GI₅₀	0.5 μM Compound: 7ao; ON1231320	Growth inhibition of human RT4 cells after 72 hrs by trypan blue assay Growth inhibition of human RT4 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
SK-HEP1	GI₅₀	0.1 μM Compound: 7ao; ON1231320	Growth inhibition of human SKHEP1 cells after 72 hrs by trypan blue assay Growth inhibition of human SKHEP1 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
SK-MEL-28	GI₅₀	0.2 μM Compound: 7ao; ON1231320	Growth inhibition of human SK-MEL-28 cells after 72 hrs by trypan blue assay Growth inhibition of human SK-MEL-28 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
SK-OV-3	GI₅₀	0.075 μM Compound: 7ao; ON1231320	Growth inhibition of human SKOV3 cells after 72 hrs by trypan blue assay Growth inhibition of human SKOV3 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
SNU-398	GI₅₀	0.15 μM Compound: 7ao; ON1231320	Growth inhibition of human SNU398 cells after 72 hrs by trypan blue assay Growth inhibition of human SNU398 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
SNU-449	GI₅₀	0.4 μM Compound: 7ao; ON1231320	Growth inhibition of human SNU449 cells after 72 hrs by trypan blue assay Growth inhibition of human SNU449 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
SNU-475	GI₅₀	7.5 μM Compound: 7ao; ON1231320	Growth inhibition of human SNU475 cells after 72 hrs by trypan blue assay Growth inhibition of human SNU475 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
SU.86.86	GI₅₀	0.4 μM Compound: 7ao; ON1231320	Growth inhibition of human SU8686 cells after 72 hrs by trypan blue assay Growth inhibition of human SU8686 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
SW780	GI₅₀	0.15 μM Compound: 7ao; ON1231320	Growth inhibition of human SW780 cells after 72 hrs by trypan blue assay Growth inhibition of human SW780 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
T-24	GI₅₀	0.15 μM Compound: 7ao; ON1231320	Growth inhibition of human T24 cells after 72 hrs by trypan blue assay Growth inhibition of human T24 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
TCC-SUP	GI₅₀	0.25 μM Compound: 7ao; ON1231320	Growth inhibition of human TCCSUP cells after 72 hrs by trypan blue assay Growth inhibition of human TCCSUP cells after 72 hrs by trypan blue assay	[PMID: 26762835]
U2OS	GI₅₀	0.035 μM Compound: 7ao; ON1231320	Growth inhibition of human U2OS cells after 72 hrs by trypan blue assay Growth inhibition of human U2OS cells after 72 hrs by trypan blue assay	[PMID: 26762835]
U-87MG ATCC	GI₅₀	0.02 μM Compound: 7ao; ON1231320	Growth inhibition of human U87 cells after 72 hrs by trypan blue assay Growth inhibition of human U87 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
U-937	GI₅₀	0.125 μM Compound: 7ao; ON1231320	Growth inhibition of human U937 cells after 72 hrs by trypan blue assay Growth inhibition of human U937 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
UMUC3	GI₅₀	0.3 μM Compound: 7ao; ON1231320	Growth inhibition of human UM-UC-3 cells after 72 hrs by trypan blue assay Growth inhibition of human UM-UC-3 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
WI-38	GI₅₀	>5 μM Compound: 7ao; ON1231320	Growth inhibition of human WI38 cells after 72 hrs by trypan blue assay Growth inhibition of human WI38 cells after 72 hrs by trypan blue assay	[PMID: 26762835]
Z-138	GI₅₀	0.2 μM Compound: 7ao; ON1231320	Growth inhibition of human Z138 cells after 72 hrs by trypan blue assay Growth inhibition of human Z138 cells after 72 hrs by trypan blue assay	[PMID: 26762835]

In Vitro

ON1231320 (Compound 7ao) has no inhibitory activity against PLK1, PLK3 and PLK4 (all IC₅₀>10 μM)^[1].
ON1231320 (0-5 μM; 24 hours) activates programmed cell death in human tumor cells^[1].
ON1231320 inhibits cell proliferation in 16 tumor cell lines (DU145, MCF-7, BT474, SK-OV-3, MIA-PaCa-2, SK-MEL-28, A549, U87, COLO-205, HELA, H1975, RAJI, U205, K562, GRANTA-519; IC₅₀= 0.035-0.2 μM)^[1].
ON1231320 does not appreciably inhibit tubulin polymerization^[1]. ON1231320 does not affect normal human fibroblasts^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Apoptosis Analysis^[1]

View Protocol

Cell Line:

U2OS cells
Concentration:

0-5 µM
Incubation Time:

24 hours
Result:

Increased the activity of Caspases 3/7 in a dose-dependent manner.
Induced apoptosis.

In Vivo

ON1231320 (Compound 7ao; 75 mg/kg; IP; alternate days (Q2D) for 20 days) results in significant inhibition of tumor growth^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

6-8 week old NCR nu/nu female mice with MDAMB-231 triple negative breast cancer cells^[1]
Dosage:

75 mg/kg
Administration:

IP; alternate days (Q2D) for 20 days
Result:

Resulted in significant inhibition of tumor growth (86.5%)

Chemical Information

CAS No. 1312471-39-8
Appearance Solid
Molecular Weight 467.45
Formula C₂₂H₁₅F₂N₅O₃S
Color Light yellow to green yellow
SMILES

O=C1C(S(=O)(C2=CC=C(F)C=C2F)=O)=CC3=CN=C(NC4=CC5=C(NC=C5)C=C4)N=C3N1C
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (3)

All Cell Proliferation/Viability AssayCell Migration/Invasion AssayFlow Cytometry

Sort by:

Journal Impact Factor

Comput Struct Biotechnol J

A deep tabular data learning model predicting cisplatin sensitivity identifies BCL2L1 dependency in cancer. [Abstract]

2023 Jan 16:21:956-964. PMID: 36733702
Transl Cancer Res

Integrative analysis of polo-like kinase family identifies a prognostic signature and validates PLK2 as a therapeutic target in glioma. [Abstract]

2025 Oct 31;14(10):6348-6363. PMID: 41234853

ON1231320 purchased from MedChemExpress. Usage Cited in: Transl Cancer Res. 2025 Oct 31;14(10):6348-6363. [Abstract]

CCK-8 assay showing that ON1231320 inhibits the proliferation of U251MG cells in a time- and dose-dependent manner.

ON1231320 purchased from MedChemExpress. Usage Cited in: Transl Cancer Res. 2025 Oct 31;14(10):6348-6363. [Abstract]

Wound healing experiments showed that, observed under an inverted microscope at 100x magnification, the migration ability of U251MG cells decreased after 24 hours of treatment with ON1231320.

ON1231320 purchased from MedChemExpress. Usage Cited in: Transl Cancer Res. 2025 Oct 31;14(10):6348-6363. [Abstract]

Flow cytometry analysis showed that after treatment with 100 nM ON1231320 for 24 hours, the DNA content of U251MG cells increased and the proportion of cells in the G2/M phase increased.
SSRN

2026 May 19.

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (106.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1393 mL

10.6963 mL

21.3927 mL

5 mM

0.4279 mL

2.1393 mL

4.2785 mL

10 mM

0.2139 mL

1.0696 mL

2.1393 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (5.35 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocols

All Cell Biology Signal Pathway Related Animals and Diseases

Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. M V Ramana Reddy, et al. Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2). Bioorg Med Chem. 2016 Feb 15;24(4):521-44. [Content Brief]

[2]. Shashidhar S. Jatiani, et al. Abstract 643: Targeting cancer with a selective ATP-mimetic inhibitor of polo like kinase-2.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1393 mL	10.6963 mL	21.3927 mL	53.4817 mL
	5 mM	0.4279 mL	2.1393 mL	4.2785 mL	10.6963 mL
	10 mM	0.2139 mL	1.0696 mL	2.1393 mL	5.3482 mL
	15 mM	0.1426 mL	0.7131 mL	1.4262 mL	3.5654 mL
	20 mM	0.1070 mL	0.5348 mL	1.0696 mL	2.6741 mL
	25 mM	0.0856 mL	0.4279 mL	0.8557 mL	2.1393 mL
	30 mM	0.0713 mL	0.3565 mL	0.7131 mL	1.7827 mL
	40 mM	0.0535 mL	0.2674 mL	0.5348 mL	1.3370 mL
	50 mM	0.0428 mL	0.2139 mL	0.4279 mL	1.0696 mL
	60 mM	0.0357 mL	0.1783 mL	0.3565 mL	0.8914 mL
	80 mM	0.0267 mL	0.1337 mL	0.2674 mL	0.6685 mL
	100 mM	0.0214 mL	0.1070 mL	0.2139 mL	0.5348 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

ON1231320

Publications Citing Use of MedChemExpress (MCE) ON1231320

All Polo-like Kinase (PLK) Isoforms